A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

• ClinicalTrials.gov Identifier: NCT04984356
• Recruitment Status: Active, not recruiting
• First Posted: July 30, 2021
• Last Update Posted: November 24, 2023
• Sponsor: Wugen, Inc.
• Information provided by (Responsible Party): Wugen, Inc.

Tracking Information

• First Submitted Date: July 29, 2021
• First Posted Date: July 30, 2021
• Last Update Posted Date: November 24, 2023
• Actual Study Start Date: January 14, 2022
• Estimated Primary Completion Date: May 2026 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 2, 2023)

• Incidence of Adverse Events of WU-CART-007 as assessed by CTCAE v5 [ Time Frame: 24 months ]
  Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of consent until end of study visit
• Maximum Tolerated Dose (MTD) [ Time Frame: up to 28 days from first dose ]
  Maximum tolerated or administered dose of WU-CART-007
• Composite Complete Response Rate [ Time Frame: 24 months ]
  Defined as proportion of patients that achieve a complete remission (CR) + complete remission with incomplete hematologic recover ( CRi) + CR with partial hematologic recovery (CRh)

Original Primary Outcome Measures (submitted: July 29, 2021)

• Incidence of Adverse Events of WU-CART-007 as assessed by CTCAE v5 [ Time Frame: 24 months ]
  Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of consent until end of study visit
• Maximum Tolerated Dose (MTD) [ Time Frame: up to 28 days from first dose ]
  Maximum tolerated or administered dose of WU-CART-007
• Overall Response Rate (ORR) [ Time Frame: 24 months ]
  ORR is defined as proportion of patients that achieve complete remission (CR) + complete remission with incomplete hematologic recover ( Cri)
• Duration of Response [ Time Frame: 24 months ]
  Time of response to the time of disease relapse, progression or death due to any cause, whichever occurs first
• Progression Free Survival [ Time Frame: 24 months ]
  Time from study drug administration (Day 1) to disease progression

Current Secondary Outcome Measures (submitted: August 2, 2023)

• Overall Survival [ Time Frame: 24 months ]
  Time from study drug administration (Day 1) to death on study
• Objective Response Rate [ Time Frame: 24 months ]
  ORR is defined as proportion of patients that achieve complete remission (CR) + complete remission with incomplete hematologic recover ( CRi) + CR with partial hematologic recovery (CRh), morphologic leukemia free state (MLFS, and partial response (PR) in patients with EMD only
• Duration of Response [ Time Frame: 24 months ]
  Time of response to the time of disease relapse, progression or death due to any cause. whichever occurs first
• Hematopoietic Stem Cell Transplant (HSCT) rate [ Time Frame: 24 months ]
  Rate of successful transition to HSCT through study treatment

Original Secondary Outcome Measures (submitted: July 29, 2021)

• Overall Survival [ Time Frame: 24 months ]
  Time from study drug administration (Day 1) to death on study
• Hematopoietic Stem Cell Transplant (HSCT) rate [ Time Frame: 24 months ]
  Rate of successful transition to HSCT through study treatment

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
• Official Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
• Brief Summary: The main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
• Detailed Description: This is a first-in-human, multicenter, Phase 1/2, single-agent study in patients with R/R T-ALL/T-LBL who have exhausted other treatment options. The study will consist of two phases, Phase 1 and Phase 2. During the Dose Escalation segment (Phase 1) up to 24 patients will be treated with 1 dose of WU-CART-007, in up to 4 dose levels until maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined. The dose escalation segment will enroll successive cohorts of 3 to 6 patients using a standard 3 + 3 design. Once the recommended phase 2 dose (RP2D) is defined, the Phase 2 portion (Cohort Expansion) will enroll expansion cohorts.
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2

Study Design

Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description:

There are two parts to this study. Phase 1 will comprise of Dose Escalation, and Phase 2 Cohort Expansion.

Phase 1 will determine the safety and tolerability of a single dose of WU-CART-007 and define the RP2D.

The Cohort Expansion Phase, will further define the safety and evaluate the initial efficacy of WU-CART-007 at the dose established from the Phase 1 Dose Escalation segment.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition

• T-cell Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Intervention

Biological: WU-CART-007

A single IV infusion of WU-CART-007 Cells on Day 1

Study Arms

Experimental: WU-CART-007

A CD7-directed chimeric antigen receptor (CAR) T-cell product.

A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy.

Intervention: Biological: WU-CART-007

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: July 29, 2021): 44
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: August 2026
• Estimated Primary Completion Date: May 2026 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key Inclusion/Exclusion Criteria:

Specific inclusion criteria apply to each disease subtype. In general, all patients will have:

• Evidence of relapsed or refractory T-ALL or T-LBL, as defined by World Health Organization (WHO) classification with bone marrow with ≥ 5% lymphoblasts by morphologic assessment or evidence of extramedullary disease at screening.

• Relapsed or refractory disease defined as at least one of the following criteria:

  1. Primary refractory: failure to achieve CR after induction chemotherapy, per investigator.
  2. Early Relapse: relapsed disease within 12 months of initial diagnosis.
  3. Late Relapse (relapsed refractory disease): relapsed disease after 12 months of initial diagnosis AND failure of re-induction therapy after disease recurrence.
  4. Relapsed or refractory disease after allogeneic transplant, and meet the following criteria:

  i. There must be histological confirmation of relapse after HSCT of T-ALL or T-LBL.

ii. Undergone allogeneic HSCT > 90 days prior to enrollment from a match related or unrelated donor, cord blood donor, haplo-identical, or autologous stem cells.

iii. Off all immunosuppressive medications for a minimum of 2 weeks with the exception of physiologic doses of corticosteroids.

iv. No prior history of Grade 2 or greater (per Cairo-Bishop) veno-occlusive disease (VOD)/sinusoidal obstruction syndrome, or active graft versus host disease (GvHD) (see exclusion criteria below for exceptions).

• Adequate renal, hepatic, respiratory, and cardiovascular function, as defined in the body of the protocol.
• Life expectancy >12 weeks
• Age: Lower age limit of 12 years. Adolescent ages 12-17 will be eligible for enrollment beginning at Dose Level 3 of the Dose Escalation phase, after review of safety, efficacy and cellular PK data and after consultation with the appropriate regulatory agencies.
• ECOG/Karnofsky performance status 0 or 1 at screening (Adults age >16) or Lansky Performance Status 60 and above (adolescents ≤ 16),
• Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent. For minors, legal guardian willingness to give written informed consent with patient assent, where appropriate.
• Willing to participate in WUC-007-02 for long-term follow up.

Patients will be excluded from study entry if:

• They have received previous treatment with any prior anti-CD7 therapy.
• Have not recovered from the effects of previous therapy.
• Wash-out period of at least 5 half-lives from the last dose of any investigational therapy prior to screening period and all related toxicities resolved to Grade 1 or baseline.
• Have active or latent hepatitis B or active hepatitis C, any uncontrolled infection, or untreated HIV positive.
• Have any serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• Have Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression (steroids). Grade 1 GvHD not requiring immunosuppression is acceptable and grade 2 skin GvHD if treated with topical therapy only is acceptable.
• Have psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Pregnant or nursing (lactating) women
• Require prohibited medications or treatments, eg, steroids, or anti-neoplastic agents
• Treated with anti-T cell monoclonal antibodies

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 12 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, France, Netherlands, United States

Administrative Information

• NCT Number: NCT04984356
• Other Study ID Numbers: WU-CART-007 1001
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Wugen, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Wugen, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Jan Davidson, MD; Wugen, Inc.

• PRS Account: Wugen, Inc.
• Verification Date: September 2023